Cabaletta Bio is trading 10.06% down at $1.61, with no clear company-specific catalyst identified for the October 13 decline.
- The company’s latest release located in the search was dated October 5.
- Biotech shares were broadly weak, with XBI down 2.01%; sector pressure may have contributed, but available evidence does not establish it as the direct cause of Cabaletta Bio’s larger drop.